Intracellular Bacteria and Protozoa - Intracellular Delivery: Fundamentals and Applications - page 808

Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari
PA (2000) Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and
inhibition of inflammation.. Nat Med 6: 1253-1257
Ruenraroengsak P, Cook JM, Florence AT (2010) Nanosystem drug targeting: Facing up to com-
plex realities. J Control Release 141: 265-276
Sahay G, Gautam V, Luxenhofer R, Kabanov AV (2010) The utilization of pathogen-like cellular
trafficking by single chain block copolymer. Biomaterials 31: 1757-1764
Sakagami M (2006) In vivo, in vitro and ex vivo models to assess pulmonary absorption and dis-
position of inhaled therapeutics for systemic delivery. Adv Drug Deliver Rev 58: 1030-1060
Sakamoto JH, van de Ven AL, Godin B, Blanco E, Serda RE, Grattoni A, Ziemys A, Bouamrani
A, Hu T, Ranganathan SI, De Rosa E, Martinez JO, Smid CA, Buchanan RM, Lee S-Y,
Srinivasan S, Landry M, Meyn A, Tasciotti E, Liu X, Decuzzi P, Ferrari M (2010) Enabling
individualized therapy through nanotechnology. Pharmacol Res 62: 57-89
Samuel BU, Hearn B, Mack D, Wender P, Rothbard J, Kirisits MJ, Mui E, Wernimont S, Roberts
CW, Muench SP, Rice DW, Prigge ST, Law AB, McLeod R (2003) Delivery of antimicrobials
into parasites. Proc Natl Acad Sci USA 24: 14281-14286
Sánchez G, Cuellar D, Zulantay I, Gajardo M, González-Martin G (2002) Cytotoxicity and try-
panocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol Res
35: 39-45
Santic ]M, Molmeret M, Abu Kwaik Y (2005) Modulation of biogenesis of the Francisella tula-
rensis subsp. novicida -containing phagosome in quiescent human macrophages and its matura-
tion into a phagolysosome upon activation by IFN-gamma. Cell Microbiol 7: 957- 967
Santos-Magalhães NS, Furtado Mosqueira VC (2010) Nanotechnology applied to the treatment of
malaria. Adv Drug Del Rev 62: 560-575
Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP (2010) Gelatin nanocarriers as potential
vectors for effective management of Tuberculosis. Int J Pharm 385: 143-149
Schenkman S, Andrews NW, Nussenzweig V, Robbins ES (1988) Trypanosoma cruzi invade a
mammalian epithelial cell in a polarized manner. Cell 55: 157-165
Schiffelers R, Storm G, Bakker-Woudenberg I (2001) Liposomes-encapsulated aminoglycosides
in pre-clinical and clinical studies. J Antimicrob Chemother 48: 333-344
Schluger NW (2005) The pathogenesis of tuberculosis. The first one hundred (and twenty-three)
years. Am J Respir Cell Mol Biol 32: 251-256
Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, Liesenfeld O (2001) Atovaquone
Nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxo-
plasmosis. Antimocrob Agents Chemother 45: 1771-1779
Schwab JC, Beckers CJ, Joiner KA (1994) The parasitophorous vacuole membrane surrounding
intracellular Toxoplasma gondii functions as a molecular sieve. Proc Natl Acad Sci USA 91:
509 - 513
Sepkowitz KA, Raffalli J, Riley L, Kiehn TE, Armstrong D (1995) Tuberculosis in the AIDS era.
Clin Microbiol Rev 8: 180-199
Sharma R, Saxena D, Dwivedi AK, Misra A (2001) Inhalable microparticles containing drug
combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm
Res 18: 1405-1410
Sharma A, Sharma S, Khuller GK (2004) Lectin functionalised poly(lactide-coglycolide) nano-
particles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J
Antimicrob Chemother 54: 761-766
Shipulo EV, Lyubimov II, Maksimenko OO, Vanchugova LV, Oganesyan EA, Sveshnikov PG,
Biketov SF, Severin ES, Heifets LB, Gelperina SE (2008) Development of a nanosomal
formulation of moxifloxacin based on poly (butyl-2-cyanoacrylate). Pharm Chem J 42:
145-149
Singh KK, Vingkar SK (2008) Formulation, antimalarial activity and biodistribution of oral lipid
nanoemulsion of primaquine. Int J Pharm 347: 136-143
Smith CR (1988) The spiramycin paradox. J Antimicrob Chemother 22 (Suppl. B): 1141-1444